BioSpecifics Technologies Corp. (BSTC)’s Financial Results Comparing With Intec Pharma Ltd. (NASDAQ:NTEC)

We are comparing BioSpecifics Technologies Corp. (NASDAQ:BSTC) and Intec Pharma Ltd. (NASDAQ:NTEC) on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioSpecifics Technologies Corp. 32.96M 14.76 20.05M 2.40 29.63
Intec Pharma Ltd. N/A 0.00 43.54M -1.40 0.00

Table 1 demonstrates BioSpecifics Technologies Corp. and Intec Pharma Ltd.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides BioSpecifics Technologies Corp. and Intec Pharma Ltd.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
BioSpecifics Technologies Corp. 60.83% 21.8% 20.7%
Intec Pharma Ltd. 0.00% 0% 0%

Analyst Ratings

The next table highlights the given recommendations and ratings for BioSpecifics Technologies Corp. and Intec Pharma Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioSpecifics Technologies Corp. 0 0 1 3.00
Intec Pharma Ltd. 0 0 0 0.00

The average target price of BioSpecifics Technologies Corp. is $85, with potential upside of 27.28%.

Insider and Institutional Ownership

Roughly 61.3% of BioSpecifics Technologies Corp. shares are owned by institutional investors while 39.64% of Intec Pharma Ltd. are owned by institutional investors. About 2.5% of BioSpecifics Technologies Corp.’s share are owned by insiders. Competitively, 11.81% are Intec Pharma Ltd.’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%
Intec Pharma Ltd. -5.95% 4.85% 37.69% 116.32% 34.75% 9.02%

For the past year BioSpecifics Technologies Corp. was more bullish than Intec Pharma Ltd.

Summary

BioSpecifics Technologies Corp. beats on 11 of the 11 factors Intec Pharma Ltd.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.